IgA nephropathy management: what does the future hold?

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Advances in understanding IgA nephropathy (IgAN) pathogenesis have spurred the development of targeted therapies.
• Surrogate markers for early treatment efficacy have accelerated regulatory approval for novel IgAN treatments.
• Recent clinical trial data have led to updated Kidney Disease: Improving Global Outcomes guidelines for IgAN management.

Purpose of the Study:

• To review the current landscape of IgA nephropathy (IgAN) treatments.
• To discuss the implications of newly approved and conditionally approved therapies.
• To explore future directions in IgAN management, including combination therapies and biomarker research.

Main Methods:

• Review of recent clinical trials and regulatory approvals for IgAN treatments.
• Analysis of current IgAN guidelines and their revisions.
• Discussion of emerging therapeutic strategies and the role of biomarkers.

Main Results:

• Two agents, Nefecon and sparsentan, are approved in some regions for IgAN.
• Iptacopan and atrasentan have conditional approval based on proteinuria reduction.
• A dual approach combining therapies targeting distinct pathogenic mechanisms is anticipated.

Conclusions:

• Combination therapies targeting hemodynamic, immune, galactose-deficient IgA1-generating, inflammatory, and fibrotic processes are likely the future standard of care for IgAN.
• Personalized care for IgAN necessitates further research into noninvasive biomarkers for diagnosis, prognosis, and treatment monitoring.
• The evolving treatment landscape offers new hope for managing IgA nephropathy progression.